ArticleThe Korean journal of helicobacter and upper gastrointestinal research2025
Antibiotic Resistance of Helicobacter pylori: Current Trends in Daegu-Kyungpook.
Article in The Korean journal of helicobacter and upper gastrointestinal research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Treatment of Helicobacter pylori Infection in Korea: An Evidence-Based Analysis of the Upcoming 2025 Guideline.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- Antimicrobial Resistance Patterns and Determinants ofAntibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Objectives: Recent trends have shown reduced success rates of the standard triple therapy, underscoring the need for updated data on the antimicrobial resistance of Helicobacter pylori. This study aimed to assess the antibiotic resistance rates of H. pylori strains in the Daegu-Kyungpook region and compare them with other regions in South Korea to provide evidence for eradication therapy guidelines. Methods: Between September 2022 and February 2024, samples from 100 patients aged 20-80 years with suspected H. pylori infections were collected across five medical institutions in the Daegu-Kyungpook region. The cultured strains were subjected to antimicrobial susceptibility testing. The minimum inhibitory concentrations for antibiotics were established using agar dilution methods, with breakpoints set at >0.125 μg/mL for amoxicillin, >0.25 μg/mL for clarithromycin, >1 μg/mL for tetracycline, >1 μg/mL for levofloxacin, and >8 μg/mL for metronidazole. Results: Among the 100 samples collected, cultures were performed for 98 samples, excluding 2 that tested negative in the rapid urease test or polymerase chain reaction. Of these, 73 (74%) samples were successfully cultured, while 25 (26%) failed. Among the 73 successful cultures, resistance was observed in 20 (27%) samples for amoxicillin, 25 (34%) for clarithromycin, 34 (47%) for metronidazole, 19 (26%) for tetracycline, and 27 (37%) for levofloxacin. Conclusions: This study showed an overall increasing trend in antibiotic resistance rates, particularly in clarithromycin resistance, emphasizing the need to reconsider first-line triple therapy. This study is the first multicenter investigation of H. pylori antibiotic resistance in the Daegu-Kyungpook region, contributing valuable insights for developing region-specific treatment guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.